Evidence map›Paper›PMID 33398501›Full record

ReviewDer Pathologe2021

[Molecular pathology of urogenital tumors : Recommendations from the 2019 International Society of Urological Pathology (ISUP) Consensus Conference].

Oliver Hommerding, Yves Allory, Pedram Argani, Tarek A Bismar, Lukas Bubendorf, Sofía Canete-Portillo, Alcides Chaux, Ying-Bei Chen, Liang Cheng, Antonio L Cubilla and 18 more

Open access · hybridAbstract readReviewConsensus Statement
PubMed Full text at PMC Publisher
In one paragraph

Review in Der Pathologe, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 99% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors at 20 institutions in 11 countries.

Oliver HommerdingInstitut für Pathologie, Universitätsklinikum Bonn, Venusberg-Campus 1, Gebäude 62, 53127, Bonn, Deutschland.
Yves AlloryDepartment of Pathology, Institut Curie, Saint-Cloud, Frankreich.
Pedram ArganiDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, USA.
Tarek A BismarDepartment of Pathology and Laboratory Medicine, University of Calgary Cumming School of Medicine and Alberta Public Labs, Calgary, Kanada.
Lukas BubendorfInstitut für Medizinische Genetik und Pathologie, Universitätsspital Basel, Basel, Schweiz.
Sofía Canete-PortilloPathology and Research Institute, National University of Asuncion, Asunción, Paraguay.
Alcides ChauxDepartment of Scientific Research, Norte University, Asunción, Paraguay.
Ying-Bei ChenDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, USA.
Liang ChengDepartment of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, USA.
Antonio L CubillaPathology and Research Institute and Medical Sciences of National University of Asuncion, Asunción, Paraguay.
Lars EgevadDepartment of Oncology and Pathology, Karolinska Institutet, Stockholm, Schweden.
Anthony J GillDepartment of Anatomical Pathology, NSW Health Pathology, Sidney, Australien.
David J GrignonDepartment of Pathology, Indiana University School of Medicine, Indianapolis, USA.
Arndt HartmannInstitut für Pathologie, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Deutschland.
Ondrej HesMedical Faculty and Charles University Hospital Plzen, Charles University, Pilsen, Tschechien.
Muhammad T IdreesPathology, Indiana University School of Medicine, Indianapolis, USA.
Chia-Sui KaoDepartment of Pathology, Stanford University School of Medicine, Stanford, USA.
Margaret A KnowlesDivison of Molecular Medicine, Leeds Institute of Molecular Research at St James's, St James's University Hospital, Leeds, Großbritannien.
Leendert H J LooijengaPrincess Máxima Center for Pediatric Oncology, Utrecht, Niederlande.
Tamara L LotanDepartments of Pathology, Oncology and Urology, Johns Hopkins University, Baltimore, USA.
Colin C PritchardDepartment of Laboratory Medicine, University of Washington, Seattle, USA.
Mark A RubinDepartment for Biomedical Research, University of Bern and Bern Center for Precision Medicine, Bern, Schweiz.
Scott A TomlinsDepartment of Pathology, Urology and Rogel Cancer Center, University of Michigan Medical School, Ann Arbor, USA.
Theodorus H Van der KwastLaboratory Medicine Program, University Health Network; Princess Margaret Cancer Centre, University of Toronto, Toronto, Kanada.
Elsa F VelazquezInform Diagnostics and Tufts University, Boston, USA.
Joshua I WarrickDepartment of Pathology, Penn State College of Medicine, Hershey, USA.
Sean R WilliamsonDepartment of Pathology and Laboratory Medicine and Henry Ford Cancer Institute, Henry Ford Health System, Detroit, USA.
Glen KristiansenInstitut für Pathologie, Universitätsklinikum Bonn, Venusberg-Campus 1, Gebäude 62, 53127, Bonn, Deutschland. glen.kristiansen@ukb.uni-bonn.de.
Indiana University – Purdue University Indianapolis · USUniversidad Nacional de Asunción · PYUniversity Hospital Bonn · DEIndiana University School of MedicineInstitut Curie · FRJohns Hopkins Medicine · USJohns Hopkins University · USKarolinska Institutet · SEMemorial Sloan Kettering Cancer Center · USNew South Wales Department of Health · AUPenn State Milton S. Hershey Medical Center · USPrincess Máxima Center · NLStanford University · USSt James's University Hospital · GBTufts University · USUniversidad del Norte · PYUniversitätsklinikum Erlangen · DEUniversity Health Network · CAUniversity Hospital of Basel · CHUniversity Hospital Plzen · CZ

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Comprehensive understanding of molecular principles in cancer and the diversification of oncological therapy promise individual therapeutic concepts, which have not yet found their way into urogenital cancer therapy. In March 2019 the International Society of Urogenital Pathology (ISUP) therefore held a consensus conference on recommendations for molecular diagnostics of genitourinary tumors, which were published in five separate manuscripts and are summarized in this article.In preparation for the conference, a comprehensive survey of current practices for molecular testing of urogenital tumors was carried out by members of the ISUP. At the conference, the results and the corresponding background information were presented by five working groups and recommendations for action for diagnostics were developed. An agreement between 66% of the conference participants was defined as consensus.

Indexed as

Prostatic NeoplasmsUrogenital NeoplasmsHumansMalePathology, MolecularBladder cancerKidney cancerMolecular biomarkerProstate cancerTargeted therapy

Identifiers

PMID33398501
PMCPMC8084837
OpenAlexW3120472630

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.